Suppr超能文献

RACK1的过表达通过增强上皮-间质转化促进转移并预测人类胶质瘤的不良预后。

Overexpression of RACK1 Promotes Metastasis by Enhancing Epithelial-Mesenchymal Transition and Predicts Poor Prognosis in Human Glioma.

作者信息

Lv Qiao-Li, Huang Yuan-Tao, Wang Gui-Hua, Liu Yan-Ling, Huang Jin, Qu Qiang, Sun Bao, Hu Lei, Cheng Lin, Chen Shu-Hui, Zhou Hong-Hao

机构信息

Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China.

Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha 410078, China.

出版信息

Int J Environ Res Public Health. 2016 Oct 18;13(10):1021. doi: 10.3390/ijerph13101021.

Abstract

Emerging studies show that dysregulation of the receptor of activated protein kinase C1 (RACK1) plays a crucial role in tumorigenesis and progression of various cancers. However, the biological function and underlying mechanism of RACK1 in glioma remains poorly defined. Here, we found that RACK1 was significantly up-regulated in glioma tissues compared with normal brain tissues, being closely related to clinical stage of glioma both in mRNA and protein levels. Moreover, Kaplan-Meier analysis demonstrated that patients with high RACK1 expression had a poor prognosis ( = 0.0062, HR = 1.898, 95% CI: 1.225-3.203). In vitro functional assays indicated that silencing of RACK1 could dramatically promote apoptosis and inhibit cell proliferation, migration, and invasion of glioma cells. More importantly, knockdown of RACK1 led to a vast accumulation of cells in G0/G1 phase and their reduced proportions at the S phase by suppressing the expression of G1/S transition key regulators Cyclin D1 and CDK6. Additionally, this forced down-regulation of RACK1 significantly suppressed migration and invasion via inhibiting the epithelial-mesenchymal transition (EMT) markers, such as MMP2, MMP9, ZEB1, N-Cadherin, and Integrin-β1. Collectively, our study revealed that RACK1 might act as a valuable prognostic biomarker and potential therapeutic target for glioma.

摘要

新兴研究表明,活化蛋白激酶C1受体(RACK1)的失调在多种癌症的发生和发展中起着关键作用。然而,RACK1在胶质瘤中的生物学功能和潜在机制仍不清楚。在此,我们发现与正常脑组织相比,RACK1在胶质瘤组织中显著上调,在mRNA和蛋白质水平上均与胶质瘤的临床分期密切相关。此外,Kaplan-Meier分析表明,RACK1高表达的患者预后较差(P = 0.0062,HR = 1.898,95% CI:1.225 - 3.203)。体外功能试验表明,沉默RACK1可显著促进胶质瘤细胞凋亡并抑制其增殖、迁移和侵袭。更重要的是,通过抑制G1/S转换关键调节因子细胞周期蛋白D1(Cyclin D1)和细胞周期蛋白依赖性激酶6(CDK6)的表达,敲低RACK1导致大量细胞积聚在G0/G1期,而S期细胞比例降低。此外,这种RACK1的强制下调通过抑制上皮-间质转化(EMT)标志物,如基质金属蛋白酶2(MMP2)、基质金属蛋白酶9(MMP9)、锌指蛋白E盒结合因子1(ZEB1)、N-钙黏蛋白(N-Cadherin)和整合素-β1(Integrin-β1),显著抑制迁移和侵袭。总的来说,我们的研究表明,RACK1可能是一种有价值的胶质瘤预后生物标志物和潜在治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5774/5086760/32b4ad990c9b/ijerph-13-01021-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验